-
1
-
-
84984659300
-
Preproglucagon (PPG) neurons in the hindbrain have IL-6 receptor α (IL-6Rα) and show Ca2+ influx in response to IL-6
-
Published online April 20, 2016
-
Anesten, F.B., Holt, M.K., Schéle, E., Palsdottir, V., Reimann, F., Gribble, F.M., Safari, C., Skibicka, K.P., Trapp, S., Jansson, J.O., Preproglucagon (PPG) neurons in the hindbrain have IL-6 receptor α (IL-6Rα) and show Ca2+ influx in response to IL-6. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2016, 10.1152/ajpregu.00383.2015 Published online April 20, 2016.
-
(2016)
Am. J. Physiol. Regul. Integr. Comp. Physiol.
-
-
Anesten, F.B.1
Holt, M.K.2
Schéle, E.3
Palsdottir, V.4
Reimann, F.5
Gribble, F.M.6
Safari, C.7
Skibicka, K.P.8
Trapp, S.9
Jansson, J.O.10
-
2
-
-
77951151612
-
Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4
-
Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., Watada, H., Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59 (2010), 1030–1037.
-
(2010)
Diabetes
, vol.59
, pp. 1030-1037
-
-
Arakawa, M.1
Mita, T.2
Azuma, K.3
Ebato, C.4
Goto, H.5
Nomiyama, T.6
Fujitani, Y.7
Hirose, T.8
Kawamori, R.9
Watada, H.10
-
3
-
-
84939540746
-
Cardioprotection resulting from glucagon-like peptide-1 administration involves shifting metabolic substrate utilization to increase energy efficiency in the rat heart
-
Aravindhan, K., Bao, W., Harpel, M.R., Willette, R.N., Lepore, J.J., Jucker, B.M., Cardioprotection resulting from glucagon-like peptide-1 administration involves shifting metabolic substrate utilization to increase energy efficiency in the rat heart. PLoS ONE, 10, 2015, e0130894.
-
(2015)
PLoS ONE
, vol.10
, pp. e0130894
-
-
Aravindhan, K.1
Bao, W.2
Harpel, M.R.3
Willette, R.N.4
Lepore, J.J.5
Jucker, B.M.6
-
4
-
-
84957840942
-
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
-
Armstrong, M.J., Gaunt, P., Aithal, G.P., Barton, D., Hull, D., Parker, R., Hazlehurst, J.M., Guo, K., Abouda, G., Aldersley, M.A., et al., LEAN trial team. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387 (2016), 679–690.
-
(2016)
Lancet
, vol.387
, pp. 679-690
-
-
Armstrong, M.J.1
Gaunt, P.2
Aithal, G.P.3
Barton, D.4
Hull, D.5
Parker, R.6
Hazlehurst, J.M.7
Guo, K.8
Abouda, G.9
Aldersley, M.A.10
-
5
-
-
84960521846
-
5. Glycemic targets
-
American Diabetes Association. 5. Glycemic targets. Diabetes Care 39:Suppl 1 (2016), S39–S46.
-
(2016)
Diabetes Care
, vol.39
, pp. S39-S46
-
-
-
6
-
-
84908101883
-
AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes
-
Balteau, M., Van Steenbergen, A., Timmermans, A.D., Dessy, C., Behets-Wydemans, G., Tajeddine, N., Castanares-Zapatero, D., Gilon, P., Vanoverschelde, J.L., Horman, S., et al. AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 307 (2014), H1120–H1133.
-
(2014)
Am. J. Physiol. Heart Circ. Physiol.
, vol.307
, pp. H1120-H1133
-
-
Balteau, M.1
Van Steenbergen, A.2
Timmermans, A.D.3
Dessy, C.4
Behets-Wydemans, G.5
Tajeddine, N.6
Castanares-Zapatero, D.7
Gilon, P.8
Vanoverschelde, J.L.9
Horman, S.10
-
7
-
-
43249089631
-
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways
-
Ban, K., Noyan-Ashraf, M.H., Hoefer, J., Bolz, S.S., Drucker, D.J., Husain, M., Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117 (2008), 2340–2350.
-
(2008)
Circulation
, vol.117
, pp. 2340-2350
-
-
Ban, K.1
Noyan-Ashraf, M.H.2
Hoefer, J.3
Bolz, S.S.4
Drucker, D.J.5
Husain, M.6
-
8
-
-
77950267745
-
Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor
-
Ban, K., Kim, K.H., Cho, C.K., Sauvé, M., Diamandis, E.P., Backx, P.H., Drucker, D.J., Husain, M., Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 151 (2010), 1520–1531.
-
(2010)
Endocrinology
, vol.151
, pp. 1520-1531
-
-
Ban, K.1
Kim, K.H.2
Cho, C.K.3
Sauvé, M.4
Diamandis, E.P.5
Backx, P.H.6
Drucker, D.J.7
Husain, M.8
-
9
-
-
84925060825
-
Interleukin-6 amplifies glucagon secretion: coordinated control via the brain and pancreas
-
Barnes, T.M., Otero, Y.F., Elliott, A.D., Locke, A.D., Malabanan, C.M., Coldren, A.G., Brissova, M., Piston, D.W., McGuinness, O.P., Interleukin-6 amplifies glucagon secretion: coordinated control via the brain and pancreas. Am. J. Physiol. Endocrinol. Metab. 307 (2014), E896–E905.
-
(2014)
Am. J. Physiol. Endocrinol. Metab.
, vol.307
, pp. E896-E905
-
-
Barnes, T.M.1
Otero, Y.F.2
Elliott, A.D.3
Locke, A.D.4
Malabanan, C.M.5
Coldren, A.G.6
Brissova, M.7
Piston, D.W.8
McGuinness, O.P.9
-
10
-
-
77950228684
-
Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation
-
Bjerre Knudsen, L., Madsen, L.W., Andersen, S., Almholt, K., de Boer, A.S., Drucker, D.J., Gotfredsen, C., Egerod, F.L., Hegelund, A.C., Jacobsen, H., et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151 (2010), 1473–1486.
-
(2010)
Endocrinology
, vol.151
, pp. 1473-1486
-
-
Bjerre Knudsen, L.1
Madsen, L.W.2
Andersen, S.3
Almholt, K.4
de Boer, A.S.5
Drucker, D.J.6
Gotfredsen, C.7
Egerod, F.L.8
Hegelund, A.C.9
Jacobsen, H.10
-
11
-
-
84954306378
-
Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner
-
Bułdak, Ł., Machnik, G., Bułdak, R.J., Łabuzek, K., Bołdys, A., Belowski, D., Basiak, M., Okopień, B., Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner. Pharmacol. Rep. 68 (2016), 329–337.
-
(2016)
Pharmacol. Rep.
, vol.68
, pp. 329-337
-
-
Bułdak, Ł.1
Machnik, G.2
Bułdak, R.J.3
Łabuzek, K.4
Bołdys, A.5
Belowski, D.6
Basiak, M.7
Okopień, B.8
-
12
-
-
84888120953
-
− mice
-
− mice. Atherosclerosis 231 (2013), 427–435.
-
(2013)
Atherosclerosis
, vol.231
, pp. 427-435
-
-
Burgmaier, M.1
Liberman, A.2
Möllmann, J.3
Kahles, F.4
Reith, S.5
Lebherz, C.6
Marx, N.7
Lehrke, M.8
-
13
-
-
84969776766
-
Glucagon-like peptide-1 receptor activation attenuates platelet aggregation and thrombosis
-
Cameron-Vendrig, A., Reheman, A., Siraj, M.A., Xu, X.R., Wang, Y., Lei, X., Afroze, T., Shikatani, E., El-Mounayri, O., Noyan, H., et al. Glucagon-like peptide-1 receptor activation attenuates platelet aggregation and thrombosis. Diabetes 65 (2016), 1714–1723.
-
(2016)
Diabetes
, vol.65
, pp. 1714-1723
-
-
Cameron-Vendrig, A.1
Reheman, A.2
Siraj, M.A.3
Xu, X.R.4
Wang, Y.5
Lei, X.6
Afroze, T.7
Shikatani, E.8
El-Mounayri, O.9
Noyan, H.10
-
14
-
-
84878808238
-
Pharmacology, physiology, and mechanisms of incretin hormone action
-
Campbell, J.E., Drucker, D.J., Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17 (2013), 819–837.
-
(2013)
Cell Metab.
, vol.17
, pp. 819-837
-
-
Campbell, J.E.1
Drucker, D.J.2
-
15
-
-
84879783953
-
Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes
-
Ceriello, A., Novials, A., Ortega, E., Canivell, S., La Sala, L., Pujadas, G., Esposito, K., Giugliano, D., Genovese, S., Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care 36 (2013), 2346–2350.
-
(2013)
Diabetes Care
, vol.36
, pp. 2346-2350
-
-
Ceriello, A.1
Novials, A.2
Ortega, E.3
Canivell, S.4
La Sala, L.5
Pujadas, G.6
Esposito, K.7
Giugliano, D.8
Genovese, S.9
-
16
-
-
84903511924
-
Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes
-
Ceriello, A., Novials, A., Canivell, S., La Sala, L., Pujadas, G., Esposito, K., Testa, R., Bucciarelli, L., Rondinelli, M., Genovese, S., Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes. Diabetes Care 37 (2014), 1938–1943.
-
(2014)
Diabetes Care
, vol.37
, pp. 1938-1943
-
-
Ceriello, A.1
Novials, A.2
Canivell, S.3
La Sala, L.4
Pujadas, G.5
Esposito, K.6
Testa, R.7
Bucciarelli, L.8
Rondinelli, M.9
Genovese, S.10
-
17
-
-
84897834466
-
Occurrence of spontaneous pancreatic lesions in normal and diabetic rats: a potential confounding factor in the nonclinical assessment of GLP-1-based therapies
-
Chadwick, K.D., Fletcher, A.M., Parrula, M.C., Bonner-Weir, S., Mangipudy, R.S., Janovitz, E., Graziano, M.J., Roy, D., Reilly, T.P., Occurrence of spontaneous pancreatic lesions in normal and diabetic rats: a potential confounding factor in the nonclinical assessment of GLP-1-based therapies. Diabetes 63 (2014), 1303–1314.
-
(2014)
Diabetes
, vol.63
, pp. 1303-1314
-
-
Chadwick, K.D.1
Fletcher, A.M.2
Parrula, M.C.3
Bonner-Weir, S.4
Mangipudy, R.S.5
Janovitz, E.6
Graziano, M.J.7
Roy, D.8
Reilly, T.P.9
-
18
-
-
84855483249
-
Exenatide exerts a potent antiinflammatory effect
-
Chaudhuri, A., Ghanim, H., Vora, M., Sia, C.L., Korzeniewski, K., Dhindsa, S., Makdissi, A., Dandona, P., Exenatide exerts a potent antiinflammatory effect. J. Clin. Endocrinol. Metab. 97 (2012), 198–207.
-
(2012)
J. Clin. Endocrinol. Metab.
, vol.97
, pp. 198-207
-
-
Chaudhuri, A.1
Ghanim, H.2
Vora, M.3
Sia, C.L.4
Korzeniewski, K.5
Dhindsa, S.6
Makdissi, A.7
Dandona, P.8
-
19
-
-
84954235632
-
Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
-
Chen, W.R., Hu, S.Y., Chen, Y.D., Zhang, Y., Qian, G., Wang, J., Yang, J.J., Wang, Z.F., Tian, F., Ning, Q.X., Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am. Heart J. 170 (2015), 845–854.
-
(2015)
Am. Heart J.
, vol.170
, pp. 845-854
-
-
Chen, W.R.1
Hu, S.Y.2
Chen, Y.D.3
Zhang, Y.4
Qian, G.5
Wang, J.6
Yang, J.J.7
Wang, Z.F.8
Tian, F.9
Ning, Q.X.10
-
20
-
-
84908501502
-
Glucagon-like peptide-1 receptor agonist activation ameliorates venous thrombosis-induced arteriovenous fistula failure in chronic kidney disease
-
Chien, C.T., Fan, S.C., Lin, S.C., Kuo, C.C., Yang, C.H., Yu, T.Y., Lee, S.P., Cheng, D.Y., Li, P.C., Glucagon-like peptide-1 receptor agonist activation ameliorates venous thrombosis-induced arteriovenous fistula failure in chronic kidney disease. Thromb. Haemost. 112 (2014), 1051–1064.
-
(2014)
Thromb. Haemost.
, vol.112
, pp. 1051-1064
-
-
Chien, C.T.1
Fan, S.C.2
Lin, S.C.3
Kuo, C.C.4
Yang, C.H.5
Yu, T.Y.6
Lee, S.P.7
Cheng, D.Y.8
Li, P.C.9
-
21
-
-
84959481026
-
Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial
-
Dejgaard, T.F., Frandsen, C.S., Hansen, T.S., Almdal, T., Urhammer, S., Pedersen-Bjergaard, U., Jensen, T., Jensen, A.K., Holst, J.J., Tarnow, L., et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 4 (2016), 221–232.
-
(2016)
Lancet Diabetes Endocrinol.
, vol.4
, pp. 221-232
-
-
Dejgaard, T.F.1
Frandsen, C.S.2
Hansen, T.S.3
Almdal, T.4
Urhammer, S.5
Pedersen-Bjergaard, U.6
Jensen, T.7
Jensen, A.K.8
Holst, J.J.9
Tarnow, L.10
-
22
-
-
84937006493
-
Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm
-
Devin, J.K., Pretorius, M., Nian, H., Yu, C., Billings, F.T. 4th, Brown, N.J., Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm. J. Am. Heart Assoc., 3, 2014, 10.1161/JAHA.114.001075.
-
(2014)
J. Am. Heart Assoc.
, vol.3
-
-
Devin, J.K.1
Pretorius, M.2
Nian, H.3
Yu, C.4
Billings, F.T.5
Brown, N.J.6
-
23
-
-
84901920026
-
Targeting inflammation in the treatment of type 2 diabetes: time to start
-
Donath, M.Y., Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat. Rev. Drug Discov. 13 (2014), 465–476.
-
(2014)
Nat. Rev. Drug Discov.
, vol.13
, pp. 465-476
-
-
Donath, M.Y.1
-
24
-
-
33644618433
-
The biology of incretin hormones
-
Drucker, D.J., The biology of incretin hormones. Cell Metab. 3 (2006), 153–165.
-
(2006)
Cell Metab.
, vol.3
, pp. 153-165
-
-
Drucker, D.J.1
-
25
-
-
84884583757
-
Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls
-
Drucker, D.J., Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 62 (2013), 3316–3323.
-
(2013)
Diabetes
, vol.62
, pp. 3316-3323
-
-
Drucker, D.J.1
-
26
-
-
84921915993
-
Deciphering metabolic messages from the gut drives therapeutic innovation: the 2014 Banting Lecture
-
Drucker, D.J., Deciphering metabolic messages from the gut drives therapeutic innovation: the 2014 Banting Lecture. Diabetes 64 (2015), 317–326.
-
(2015)
Diabetes
, vol.64
, pp. 317-326
-
-
Drucker, D.J.1
-
27
-
-
84960876649
-
Evolving concepts and translational relevance of enteroendocrine cell biology
-
Drucker, D.J., Evolving concepts and translational relevance of enteroendocrine cell biology. J. Clin. Endocrinol. Metab. 101 (2016), 778–786.
-
(2016)
J. Clin. Endocrinol. Metab.
, vol.101
, pp. 778-786
-
-
Drucker, D.J.1
-
28
-
-
33846006173
-
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
-
Drucker, D.J., Nauck, M.A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006), 1696–1705.
-
(2006)
Lancet
, vol.368
, pp. 1696-1705
-
-
Drucker, D.J.1
Nauck, M.A.2
-
29
-
-
80054708816
-
Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology
-
Drucker, D.J., Rosen, C.F., Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology. Diabetologia 54 (2011), 2741–2744.
-
(2011)
Diabetologia
, vol.54
, pp. 2741-2744
-
-
Drucker, D.J.1
Rosen, C.F.2
-
30
-
-
79960086290
-
The safety of incretin-based therapies—review of the scientific evidence
-
Drucker, D.J., Sherman, S.I., Bergenstal, R.M., Buse, J.B., The safety of incretin-based therapies—review of the scientific evidence. J. Clin. Endocrinol. Metab. 96 (2011), 2027–2031.
-
(2011)
J. Clin. Endocrinol. Metab.
, vol.96
, pp. 2027-2031
-
-
Drucker, D.J.1
Sherman, S.I.2
Bergenstal, R.M.3
Buse, J.B.4
-
31
-
-
84908177336
-
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
-
Dungan, K.M., Povedano, S.T., Forst, T., González, J.G., Atisso, C., Sealls, W., Fahrbach, J.L., Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 384 (2014), 1349–1357.
-
(2014)
Lancet
, vol.384
, pp. 1349-1357
-
-
Dungan, K.M.1
Povedano, S.T.2
Forst, T.3
González, J.G.4
Atisso, C.5
Sealls, W.6
Fahrbach, J.L.7
-
32
-
-
0141999599
-
Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects
-
Edwards, C.M., Todd, J.F., Ghatei, M.A., Bloom, S.R., Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects. Clin. Sci. 95 (1998), 719–724.
-
(1998)
Clin. Sci.
, vol.95
, pp. 719-724
-
-
Edwards, C.M.1
Todd, J.F.2
Ghatei, M.A.3
Bloom, S.R.4
-
33
-
-
81255157471
-
Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells
-
Ellingsgaard, H., Hauselmann, I., Schuler, B., Habib, A.M., Baggio, L.L., Meier, D.T., Eppler, E., Bouzakri, K., Wueest, S., Muller, Y.D., et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat. Med. 17 (2011), 1481–1489.
-
(2011)
Nat. Med.
, vol.17
, pp. 1481-1489
-
-
Ellingsgaard, H.1
Hauselmann, I.2
Schuler, B.3
Habib, A.M.4
Baggio, L.L.5
Meier, D.T.6
Eppler, E.7
Bouzakri, K.8
Wueest, S.9
Muller, Y.D.10
-
34
-
-
84928314796
-
Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes—a randomized, single-blinded, cross-over pilot study
-
Faber, R., Zander, M., Pena, A., Michelsen, M.M., Mygind, N.D., Prescott, E., Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes—a randomized, single-blinded, cross-over pilot study. Cardiovasc. Diabetol., 14, 2015, 41.
-
(2015)
Cardiovasc. Diabetol.
, vol.14
, pp. 41
-
-
Faber, R.1
Zander, M.2
Pena, A.3
Michelsen, M.M.4
Mygind, N.D.5
Prescott, E.6
-
35
-
-
84914666192
-
Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus
-
Ferdinand, K.C., White, W.B., Calhoun, D.A., Lonn, E.M., Sager, P.T., Brunelle, R., Jiang, H.H., Threlkeld, R.J., Robertson, K.E., Geiger, M.J., Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension 64 (2014), 731–737.
-
(2014)
Hypertension
, vol.64
, pp. 731-737
-
-
Ferdinand, K.C.1
White, W.B.2
Calhoun, D.A.3
Lonn, E.M.4
Sager, P.T.5
Brunelle, R.6
Jiang, H.H.7
Threlkeld, R.J.8
Robertson, K.E.9
Geiger, M.J.10
-
36
-
-
84962323033
-
A multicenter observational study of incretin-based drugs and heart failure
-
Filion, K.B., Azoulay, L., Platt, R.W., Dahl, M., Dormuth, C.R., Clemens, K.K., Hu, N., Paterson, J.M., Targownik, L., Turin, T.C., et al., CNODES Investigators. A multicenter observational study of incretin-based drugs and heart failure. N. Engl. J. Med. 374 (2016), 1145–1154.
-
(2016)
N. Engl. J. Med.
, vol.374
, pp. 1145-1154
-
-
Filion, K.B.1
Azoulay, L.2
Platt, R.W.3
Dahl, M.4
Dormuth, C.R.5
Clemens, K.K.6
Hu, N.7
Paterson, J.M.8
Targownik, L.9
Turin, T.C.10
-
37
-
-
84940747146
-
Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
-
Fisher, M., Petrie, M.C., Ambery, P.D., Donaldson, J., Ye, J., McMurray, J.J., Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes Endocrinol. 3 (2015), 697–703.
-
(2015)
Lancet Diabetes Endocrinol.
, vol.3
, pp. 697-703
-
-
Fisher, M.1
Petrie, M.C.2
Ambery, P.D.3
Donaldson, J.4
Ye, J.5
McMurray, J.J.6
-
38
-
-
84971350162
-
Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants with type 2 diabetes at high cardiovascular risk
-
FLAT-SUGAR Trial Investigators. Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants with type 2 diabetes at high cardiovascular risk. Diabetes Care 39 (2016), 973–981, 10.2337/dc15-2782.
-
(2016)
Diabetes Care
, vol.39
, pp. 973-981
-
-
-
40
-
-
84946079534
-
Chronic exposure to TNFα impairs secretion of glucagon-like peptide-1
-
Gagnon, J., Sauvé, M., Zhao, W., Stacey, H.M., Wiber, S.C., Bolz, S.S., Brubaker, P.L., Chronic exposure to TNFα impairs secretion of glucagon-like peptide-1. Endocrinology 156 (2015), 3950–3960.
-
(2015)
Endocrinology
, vol.156
, pp. 3950-3960
-
-
Gagnon, J.1
Sauvé, M.2
Zhao, W.3
Stacey, H.M.4
Wiber, S.C.5
Bolz, S.S.6
Brubaker, P.L.7
-
41
-
-
84903807727
-
Glucagon-like peptide-1 (7-36) but not (9-36) augments cardiac output during myocardial ischemia via a Frank-Starling mechanism
-
Goodwill, A.G., Tune, J.D., Noblet, J.N., Conteh, A.M., Sassoon, D., Casalini, E.D., Mather, K.J., Glucagon-like peptide-1 (7-36) but not (9-36) augments cardiac output during myocardial ischemia via a Frank-Starling mechanism. Basic Res. Cardiol., 109, 2014, 426.
-
(2014)
Basic Res. Cardiol.
, vol.109
, pp. 426
-
-
Goodwill, A.G.1
Tune, J.D.2
Noblet, J.N.3
Conteh, A.M.4
Sassoon, D.5
Casalini, E.D.6
Mather, K.J.7
-
42
-
-
84958620086
-
Enteroendocrine cells: chemosensors in the intestinal epithelium
-
Gribble, F.M., Reimann, F., Enteroendocrine cells: chemosensors in the intestinal epithelium. Annu. Rev. Physiol. 78 (2016), 277–299.
-
(2016)
Annu. Rev. Physiol.
, vol.78
, pp. 277-299
-
-
Gribble, F.M.1
Reimann, F.2
-
43
-
-
78650507366
-
GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons
-
Griffioen, K.J., Wan, R., Okun, E., Wang, X., Lovett-Barr, M.R., Li, Y., Mughal, M.R., Mendelowitz, D., Mattson, M.P., GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. Cardiovasc. Res. 89 (2011), 72–78.
-
(2011)
Cardiovasc. Res.
, vol.89
, pp. 72-78
-
-
Griffioen, K.J.1
Wan, R.2
Okun, E.3
Wang, X.4
Lovett-Barr, M.R.5
Li, Y.6
Mughal, M.R.7
Mendelowitz, D.8
Mattson, M.P.9
-
44
-
-
77949268923
-
Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells
-
Hadjiyanni, I., Siminovitch, K.A., Danska, J.S., Drucker, D.J., Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells. Diabetologia 53 (2010), 730–740.
-
(2010)
Diabetologia
, vol.53
, pp. 730-740
-
-
Hadjiyanni, I.1
Siminovitch, K.A.2
Danska, J.S.3
Drucker, D.J.4
-
45
-
-
77749273703
-
Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure
-
Halbirk, M., Nørrelund, H., Møller, N., Holst, J.J., Schmitz, O., Nielsen, R., Nielsen-Kudsk, J.E., Nielsen, S.S., Nielsen, T.T., Eiskjaer, H., et al. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am. J. Physiol. Heart Circ. Physiol. 298 (2010), H1096–H1102.
-
(2010)
Am. J. Physiol. Heart Circ. Physiol.
, vol.298
, pp. H1096-H1102
-
-
Halbirk, M.1
Nørrelund, H.2
Møller, N.3
Holst, J.J.4
Schmitz, O.5
Nielsen, R.6
Nielsen-Kudsk, J.E.7
Nielsen, S.S.8
Nielsen, T.T.9
Eiskjaer, H.10
-
46
-
-
84880147886
-
Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes
-
He, L., Wong, C.K., Cheung, K.K., Yau, H.C., Fu, A., Zhao, H.L., Leung, K.M., Kong, A.P., Wong, G.W., Chan, P.K., et al. Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes. J. Diabetes Investig. 4 (2013), 382–392.
-
(2013)
J. Diabetes Investig.
, vol.4
, pp. 382-392
-
-
He, L.1
Wong, C.K.2
Cheung, K.K.3
Yau, H.C.4
Fu, A.5
Zhao, H.L.6
Leung, K.M.7
Kong, A.P.8
Wong, G.W.9
Chan, P.K.10
-
47
-
-
84885300888
-
Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial
-
Hermansen, K., Bækdal, T.A., Düring, M., Pietraszek, A., Mortensen, L.S., Jørgensen, H., Flint, A., Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial. Diabetes Obes. Metab. 15 (2013), 1040–1048.
-
(2013)
Diabetes Obes. Metab.
, vol.15
, pp. 1040-1048
-
-
Hermansen, K.1
Bækdal, T.A.2
Düring, M.3
Pietraszek, A.4
Mortensen, L.S.5
Jørgensen, H.6
Flint, A.7
-
48
-
-
80054681735
-
Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis
-
Hogan, A.E., Tobin, A.M., Ahern, T., Corrigan, M.A., Gaoatswe, G., Jackson, R., O'Reilly, V., Lynch, L., Doherty, D.G., Moynagh, P.N., et al. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia 54 (2011), 2745–2754.
-
(2011)
Diabetologia
, vol.54
, pp. 2745-2754
-
-
Hogan, A.E.1
Tobin, A.M.2
Ahern, T.3
Corrigan, M.A.4
Gaoatswe, G.5
Jackson, R.6
O'Reilly, V.7
Lynch, L.8
Doherty, D.G.9
Moynagh, P.N.10
-
49
-
-
84896080822
-
Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus
-
Hogan, A.E., Gaoatswe, G., Lynch, L., Corrigan, M.A., Woods, C., O'Connell, J., O'Shea, D., Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia 57 (2014), 781–784.
-
(2014)
Diabetologia
, vol.57
, pp. 781-784
-
-
Hogan, A.E.1
Gaoatswe, G.2
Lynch, L.3
Corrigan, M.A.4
Woods, C.5
O'Connell, J.6
O'Shea, D.7
-
50
-
-
84901768284
-
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
-
Holman, R.R., Sourij, H., Califf, R.M., Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 383 (2014), 2008–2017.
-
(2014)
Lancet
, vol.383
, pp. 2008-2017
-
-
Holman, R.R.1
Sourij, H.2
Califf, R.M.3
-
51
-
-
84953261551
-
Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP
-
Hou, Y., Ernst, S.A., Heidenreich, K., Williams, J.A., Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP. Am. J. Physiol. Gastrointest. Liver Physiol. 310 (2016), G26–G33.
-
(2016)
Am. J. Physiol. Gastrointest. Liver Physiol.
, vol.310
, pp. G26-G33
-
-
Hou, Y.1
Ernst, S.A.2
Heidenreich, K.3
Williams, J.A.4
-
52
-
-
77949273334
-
The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice
-
Hsieh, J., Longuet, C., Baker, C.L., Qin, B., Federico, L.M., Drucker, D.J., Adeli, K., The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 53 (2010), 552–561.
-
(2010)
Diabetologia
, vol.53
, pp. 552-561
-
-
Hsieh, J.1
Longuet, C.2
Baker, C.L.3
Qin, B.4
Federico, L.M.5
Drucker, D.J.6
Adeli, K.7
-
53
-
-
84927740170
-
Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow
-
Jensen, E.P., Poulsen, S.S., Kissow, H., Holstein-Rathlou, N.H., Deacon, C.F., Jensen, B.L., Holst, J.J., Sorensen, C.M., Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow. Am. J. Physiol. Renal Physiol. 308 (2015), F867–F877.
-
(2015)
Am. J. Physiol. Renal Physiol.
, vol.308
, pp. F867-F877
-
-
Jensen, E.P.1
Poulsen, S.S.2
Kissow, H.3
Holstein-Rathlou, N.H.4
Deacon, C.F.5
Jensen, B.L.6
Holst, J.J.7
Sorensen, C.M.8
-
54
-
-
79952932916
-
Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes
-
Jimenez-Solem, E., Rasmussen, M.H., Christensen, M., Knop, F.K., Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes. Curr. Opin. Mol. Ther. 12 (2010), 790–797.
-
(2010)
Curr. Opin. Mol. Ther.
, vol.12
, pp. 790-797
-
-
Jimenez-Solem, E.1
Rasmussen, M.H.2
Christensen, M.3
Knop, F.K.4
-
55
-
-
84901465015
-
A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study)
-
Jorsal, A., Wiggers, H., Holmager, P., Nilsson, B., Nielsen, R., Boesgaard, T.W., Kumme, A., Møller, J.E., Videbæk, L., Kistorp, C., et al. A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study). BMJ Open, 4, 2014, e004885.
-
(2014)
BMJ Open
, vol.4
, pp. e004885
-
-
Jorsal, A.1
Wiggers, H.2
Holmager, P.3
Nilsson, B.4
Nielsen, R.5
Boesgaard, T.W.6
Kumme, A.7
Møller, J.E.8
Videbæk, L.9
Kistorp, C.10
-
56
-
-
84926343937
-
The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls
-
Kahal, H., Aburima, A., Ungvari, T., Rigby, A.S., Coady, A.M., Vince, R.V., Ajjan, R.A., Kilpatrick, E.S., Naseem, K.M., Atkin, S.L., The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls. BMC Endocr. Disord., 15, 2015, 14.
-
(2015)
BMC Endocr. Disord.
, vol.15
, pp. 14
-
-
Kahal, H.1
Aburima, A.2
Ungvari, T.3
Rigby, A.S.4
Coady, A.M.5
Vince, R.V.6
Ajjan, R.A.7
Kilpatrick, E.S.8
Naseem, K.M.9
Atkin, S.L.10
-
57
-
-
84907481915
-
GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering
-
Kahles, F., Meyer, C., Möllmann, J., Diebold, S., Findeisen, H.M., Lebherz, C., Trautwein, C., Koch, A., Tacke, F., Marx, N., Lehrke, M., GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering. Diabetes 63 (2014), 3221–3229.
-
(2014)
Diabetes
, vol.63
, pp. 3221-3229
-
-
Kahles, F.1
Meyer, C.2
Möllmann, J.3
Diebold, S.4
Findeisen, H.M.5
Lebherz, C.6
Trautwein, C.7
Koch, A.8
Tacke, F.9
Marx, N.10
Lehrke, M.11
-
58
-
-
84923899654
-
Direct effect of incretin hormones on glucose and glycerol metabolism and hemodynamics
-
Karstoft, K., Mortensen, S.P., Knudsen, S.H., Solomon, T.P., Direct effect of incretin hormones on glucose and glycerol metabolism and hemodynamics. Am. J. Physiol. Endocrinol. Metab. 308 (2015), E426–E433.
-
(2015)
Am. J. Physiol. Endocrinol. Metab.
, vol.308
, pp. E426-E433
-
-
Karstoft, K.1
Mortensen, S.P.2
Knudsen, S.H.3
Solomon, T.P.4
-
59
-
-
84866701959
-
Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects
-
Keller, J., Trautmann, M.E., Haber, H., Tham, L.S., Hunt, T., Mace, K., Linnebjerg, H., Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects. Regul. Pept. 179 (2012), 77–83.
-
(2012)
Regul. Pept.
, vol.179
, pp. 77-83
-
-
Keller, J.1
Trautmann, M.E.2
Haber, H.3
Tham, L.S.4
Hunt, T.5
Mace, K.6
Linnebjerg, H.7
-
60
-
-
84861944029
-
Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial
-
Kelly, A.S., Bergenstal, R.M., Gonzalez-Campoy, J.M., Katz, H., Bank, A.J., Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc. Diabetol., 11, 2012, 64.
-
(2012)
Cardiovasc. Diabetol.
, vol.11
, pp. 64
-
-
Kelly, A.S.1
Bergenstal, R.M.2
Gonzalez-Campoy, J.M.3
Katz, H.4
Bank, A.J.5
-
61
-
-
84921931382
-
Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study
-
Khunti, K., Davies, M., Majeed, A., Thorsted, B.L., Wolden, M.L., Paul, S.K., Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care 38 (2015), 316–322.
-
(2015)
Diabetes Care
, vol.38
, pp. 316-322
-
-
Khunti, K.1
Davies, M.2
Majeed, A.3
Thorsted, B.L.4
Wolden, M.L.5
Paul, S.K.6
-
62
-
-
84877317750
-
GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure
-
Kim, M., Platt, M.J., Shibasaki, T., Quaggin, S.E., Backx, P.H., Seino, S., Simpson, J.A., Drucker, D.J., GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat. Med. 19 (2013), 567–575.
-
(2013)
Nat. Med.
, vol.19
, pp. 567-575
-
-
Kim, M.1
Platt, M.J.2
Shibasaki, T.3
Quaggin, S.E.4
Backx, P.H.5
Seino, S.6
Simpson, J.A.7
Drucker, D.J.8
-
63
-
-
70349120958
-
Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice
-
Koehler, J.A., Baggio, L.L., Lamont, B.J., Ali, S., Drucker, D.J., Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 58 (2009), 2148–2161.
-
(2009)
Diabetes
, vol.58
, pp. 2148-2161
-
-
Koehler, J.A.1
Baggio, L.L.2
Lamont, B.J.3
Ali, S.4
Drucker, D.J.5
-
64
-
-
84928206311
-
Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis
-
Koehler, J.A., Baggio, L.L., Cao, X., Abdulla, T., Campbell, J.E., Secher, T., Jelsing, J., Larsen, B., Drucker, D.J., Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis. Diabetes 64 (2015), 1046–1056.
-
(2015)
Diabetes
, vol.64
, pp. 1046-1056
-
-
Koehler, J.A.1
Baggio, L.L.2
Cao, X.3
Abdulla, T.4
Campbell, J.E.5
Secher, T.6
Jelsing, J.7
Larsen, B.8
Drucker, D.J.9
-
65
-
-
84924428027
-
GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7
-
Koehler, J.A., Baggio, L.L., Yusta, B., Longuet, C., Rowland, K.J., Cao, X., Holland, D., Brubaker, P.L., Drucker, D.J., GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7. Cell Metab. 21 (2015), 379–391, 10.1016/j.cmet.2015.1002.1005.
-
(2015)
Cell Metab.
, vol.21
, pp. 379-391
-
-
Koehler, J.A.1
Baggio, L.L.2
Yusta, B.3
Longuet, C.4
Rowland, K.J.5
Cao, X.6
Holland, D.7
Brubaker, P.L.8
Drucker, D.J.9
-
66
-
-
84949110416
-
Exenatide protects against glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans
-
Koska, J., Sands, M., Burciu, C., D'Souza, K.M., Raravikar, K., Liu, J., Truran, S., Franco, D.A., Schwartz, E.A., Schwenke, D.C., et al. Exenatide protects against glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans. Diabetes 64 (2015), 2624–2635.
-
(2015)
Diabetes
, vol.64
, pp. 2624-2635
-
-
Koska, J.1
Sands, M.2
Burciu, C.3
D'Souza, K.M.4
Raravikar, K.5
Liu, J.6
Truran, S.7
Franco, D.A.8
Schwartz, E.A.9
Schwenke, D.C.10
-
67
-
-
84901341959
-
Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism
-
Krasner, N.M., Ido, Y., Ruderman, N.B., Cacicedo, J.M., Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism. PLoS ONE, 9, 2014, e97554.
-
(2014)
PLoS ONE
, vol.9
, pp. e97554
-
-
Krasner, N.M.1
Ido, Y.2
Ruderman, N.B.3
Cacicedo, J.M.4
-
68
-
-
84957562919
-
Oxyntomodulin regulates resetting of the liver circadian clock by food
-
Landgraf, D., Tsang, A.H., Leliavski, A., Koch, C.E., Barclay, J.L., Drucker, D.J., Oster, H., Oxyntomodulin regulates resetting of the liver circadian clock by food. eLife, 4, 2015, e06253.
-
(2015)
eLife
, vol.4
, pp. e06253
-
-
Landgraf, D.1
Tsang, A.H.2
Leliavski, A.3
Koch, C.E.4
Barclay, J.L.5
Drucker, D.J.6
Oster, H.7
-
69
-
-
84957439021
-
Interleukin-6 predicts inflammation-induced increase of Glucagon-like peptide-1 in humans in response to cardiac surgery with association to parameters of glucose metabolism
-
Lebherz, C., Kahles, F., Piotrowski, K., Vogeser, M., Foldenauer, A.C., Nassau, K., Kilger, E., Marx, N., Parhofer, K.G., Lehrke, M., Interleukin-6 predicts inflammation-induced increase of Glucagon-like peptide-1 in humans in response to cardiac surgery with association to parameters of glucose metabolism. Cardiovasc. Diabetol., 15, 2016, 21.
-
(2016)
Cardiovasc. Diabetol.
, vol.15
, pp. 21
-
-
Lebherz, C.1
Kahles, F.2
Piotrowski, K.3
Vogeser, M.4
Foldenauer, A.C.5
Nassau, K.6
Kilger, E.7
Marx, N.8
Parhofer, K.G.9
Lehrke, M.10
-
70
-
-
84927615412
-
The effects of TNF-α on GLP-1-stimulated plasma glucose kinetics
-
Lehrskov-Schmidt, L., Lehrskov-Schmidt, L., Nielsen, S.T., Holst, J.J., Møller, K., Solomon, T.P., The effects of TNF-α on GLP-1-stimulated plasma glucose kinetics. J. Clin. Endocrinol. Metab. 100 (2015), E616–E622.
-
(2015)
J. Clin. Endocrinol. Metab.
, vol.100
, pp. E616-E622
-
-
Lehrskov-Schmidt, L.1
Lehrskov-Schmidt, L.2
Nielsen, S.T.3
Holst, J.J.4
Møller, K.5
Solomon, T.P.6
-
71
-
-
84962068591
-
Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction
-
Published online March 25, 2016
-
Lepore, J.J., Olson, E., Demopoulos, L., Haws, T., Fang, Z., Barbour, A.M., Fossler, M., Davila-Roman, V.G., Russell, S.D., Gropler, R.J., Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction. JACC Heart Fail., 2016, 10.1016/j.jchf.2016.01.008 Published online March 25, 2016.
-
(2016)
JACC Heart Fail.
-
-
Lepore, J.J.1
Olson, E.2
Demopoulos, L.3
Haws, T.4
Fang, Z.5
Barbour, A.M.6
Fossler, M.7
Davila-Roman, V.G.8
Russell, S.D.9
Gropler, R.J.10
-
72
-
-
84921961337
-
Inflammation and immunity in diseases of the arterial tree: players and layers
-
Libby, P., Hansson, G.K., Inflammation and immunity in diseases of the arterial tree: players and layers. Circ. Res. 116 (2015), 307–311.
-
(2015)
Circ. Res.
, vol.116
, pp. 307-311
-
-
Libby, P.1
Hansson, G.K.2
-
73
-
-
84863560602
-
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
-
Lønborg, J., Vejlstrup, N., Kelbæk, H., Bøtker, H.E., Kim, W.Y., Mathiasen, A.B., Jørgensen, E., Helqvist, S., Saunamäki, K., Clemmensen, P., et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur. Heart J. 33 (2012), 1491–1499.
-
(2012)
Eur. Heart J.
, vol.33
, pp. 1491-1499
-
-
Lønborg, J.1
Vejlstrup, N.2
Kelbæk, H.3
Bøtker, H.E.4
Kim, W.Y.5
Mathiasen, A.B.6
Jørgensen, E.7
Helqvist, S.8
Saunamäki, K.9
Clemmensen, P.10
-
74
-
-
84903177155
-
Impact of acute hyperglycemia on myocardial infarct size, area at risk, and salvage in patients with STEMI and the association with exenatide treatment: results from a randomized study
-
Lønborg, J., Vejlstrup, N., Kelbæk, H., Nepper-Christensen, L., Jørgensen, E., Helqvist, S., Holmvang, L., Saunamäki, K., Bøtker, H.E., Kim, W.Y., et al. Impact of acute hyperglycemia on myocardial infarct size, area at risk, and salvage in patients with STEMI and the association with exenatide treatment: results from a randomized study. Diabetes 63 (2014), 2474–2485, 10.2337/db13-1849.
-
(2014)
Diabetes
, vol.63
, pp. 2474-2485
-
-
Lønborg, J.1
Vejlstrup, N.2
Kelbæk, H.3
Nepper-Christensen, L.4
Jørgensen, E.5
Helqvist, S.6
Holmvang, L.7
Saunamäki, K.8
Bøtker, H.E.9
Kim, W.Y.10
-
75
-
-
84920053430
-
Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes
-
Lovshin, J.A., Barnie, A., DeAlmeida, A., Logan, A., Zinman, B., Drucker, D.J., Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care 38 (2015), 132–139.
-
(2015)
Diabetes Care
, vol.38
, pp. 132-139
-
-
Lovshin, J.A.1
Barnie, A.2
DeAlmeida, A.3
Logan, A.4
Zinman, B.5
Drucker, D.J.6
-
76
-
-
84857422717
-
GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation
-
Madsen, L.W., Knauf, J.A., Gotfredsen, C., Pilling, A., Sjögren, I., Andersen, S., Andersen, L., de Boer, A.S., Manova, K., Barlas, A., et al. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology 153 (2012), 1538–1547.
-
(2012)
Endocrinology
, vol.153
, pp. 1538-1547
-
-
Madsen, L.W.1
Knauf, J.A.2
Gotfredsen, C.3
Pilling, A.4
Sjögren, I.5
Andersen, S.6
Andersen, L.7
de Boer, A.S.8
Manova, K.9
Barlas, A.10
-
77
-
-
84907420900
-
GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study
-
Margulies, K.B., Anstrom, K.J., Hernandez, A.F., Redfield, M.M., Shah, M.R., Braunwald, E., Cappola, T.P., Heart Failure Clinical Research Network. GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study. Circ Heart Fail 7 (2014), 673–679.
-
(2014)
Circ Heart Fail
, vol.7
, pp. 673-679
-
-
Margulies, K.B.1
Anstrom, K.J.2
Hernandez, A.F.3
Redfield, M.M.4
Shah, M.R.5
Braunwald, E.6
Cappola, T.P.7
-
78
-
-
84886946727
-
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial
-
823–30.e5
-
Marso, S.P., Poulter, N.R., Nissen, S.E., Nauck, M.A., Zinman, B., Daniels, G.H., Pocock, S., Steinberg, W.M., Bergenstal, R.M., Mann, J.F., et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am. Heart J., 166, 2013 823–30.e5.
-
(2013)
Am. Heart J.
, vol.166
-
-
Marso, S.P.1
Poulter, N.R.2
Nissen, S.E.3
Nauck, M.A.4
Zinman, B.5
Daniels, G.H.6
Pocock, S.7
Steinberg, W.M.8
Bergenstal, R.M.9
Mann, J.F.10
-
79
-
-
84978839381
-
Liraglutide and cardiovascular outcomes in type 2 diabetes
-
Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F.E., Nauck, M.A., Nissen, S.E., Pocock, S., Poulter, N.R., Ravn, L.S., et al., LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med., 2016, 10.1056/NEJMoa1603827.
-
(2016)
N. Engl. J. Med.
-
-
Marso, S.P.1
Daniels, G.H.2
Brown-Frandsen, K.3
Kristensen, P.4
Mann, J.F.E.5
Nauck, M.A.6
Nissen, S.E.7
Pocock, S.8
Poulter, N.R.9
Ravn, L.S.10
-
80
-
-
84923165949
-
Pre-treatment with glucagon-like peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization
-
McCormick, L.M., Hoole, S.P., White, P.A., Read, P.A., Axell, R.G., Clarke, S.J., O'Sullivan, M., West, N.E., Dutka, D.P., Pre-treatment with glucagon-like peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization. JACC Cardiovasc. Interv. 8 (2015), 292–301.
-
(2015)
JACC Cardiovasc. Interv.
, vol.8
, pp. 292-301
-
-
McCormick, L.M.1
Hoole, S.P.2
White, P.A.3
Read, P.A.4
Axell, R.G.5
Clarke, S.J.6
O'Sullivan, M.7
West, N.E.8
Dutka, D.P.9
-
81
-
-
84870054636
-
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
-
Meier, J.J., GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 8 (2012), 728–742.
-
(2012)
Nat. Rev. Endocrinol.
, vol.8
, pp. 728-742
-
-
Meier, J.J.1
-
82
-
-
84903519951
-
Risk of pancreatitis in patients treated with incretin-based therapies
-
Meier, J.J., Nauck, M.A., Risk of pancreatitis in patients treated with incretin-based therapies. Diabetologia 57 (2014), 1320–1324.
-
(2014)
Diabetologia
, vol.57
, pp. 1320-1324
-
-
Meier, J.J.1
Nauck, M.A.2
-
83
-
-
84942374717
-
Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial
-
Meier, J.J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.V., Menge, B.A., Forst, T., Kapitza, C., Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care 38 (2015), 1263–1273.
-
(2015)
Diabetes Care
, vol.38
, pp. 1263-1273
-
-
Meier, J.J.1
Rosenstock, J.2
Hincelin-Méry, A.3
Roy-Duval, C.4
Delfolie, A.5
Coester, H.V.6
Menge, B.A.7
Forst, T.8
Kapitza, C.9
-
84
-
-
84920095184
-
Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors
-
Mulvihill, E.E., Drucker, D.J., Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr. Rev. 35 (2014), 992–1019.
-
(2014)
Endocr. Rev.
, vol.35
, pp. 992-1019
-
-
Mulvihill, E.E.1
Drucker, D.J.2
-
85
-
-
84962388454
-
Inhibition of dipeptidyl peptidase-4 impairs ventricular function and promotes cardiac fibrosis in high fat-fed diabetic mice
-
Mulvihill, E.E., Varin, E.M., Ussher, J.R., Campbell, J.E., Bang, K.W., Abdullah, T., Baggio, L.L., Drucker, D.J., Inhibition of dipeptidyl peptidase-4 impairs ventricular function and promotes cardiac fibrosis in high fat-fed diabetic mice. Diabetes 65 (2016), 742–754.
-
(2016)
Diabetes
, vol.65
, pp. 742-754
-
-
Mulvihill, E.E.1
Varin, E.M.2
Ussher, J.R.3
Campbell, J.E.4
Bang, K.W.5
Abdullah, T.6
Baggio, L.L.7
Drucker, D.J.8
-
86
-
-
80054110585
-
Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice
-
Nagashima, M., Watanabe, T., Terasaki, M., Tomoyasu, M., Nohtomi, K., Kim-Kaneyama, J., Miyazaki, A., Hirano, T., Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia 54 (2011), 2649–2659.
-
(2011)
Diabetologia
, vol.54
, pp. 2649-2659
-
-
Nagashima, M.1
Watanabe, T.2
Terasaki, M.3
Tomoyasu, M.4
Nohtomi, K.5
Kim-Kaneyama, J.6
Miyazaki, A.7
Hirano, T.8
-
87
-
-
84962097356
-
Effects of GLP-1 receptor agonists on heart rate and the autonomic nervous system using Holter electrocardiography and power spectrum analysis of heart rate variability
-
Nakatani, Y., Kawabe, A., Matsumura, M., Aso, Y., Yasu, T., Banba, N., Nakamoto, T., Effects of GLP-1 receptor agonists on heart rate and the autonomic nervous system using Holter electrocardiography and power spectrum analysis of heart rate variability. Diabetes Care 39 (2016), e22–e23.
-
(2016)
Diabetes Care
, vol.39
, pp. e22-e23
-
-
Nakatani, Y.1
Kawabe, A.2
Matsumura, M.3
Aso, Y.4
Yasu, T.5
Banba, N.6
Nakamoto, T.7
-
88
-
-
84912035416
-
The effect of liraglutide on endothelial function in patients with type 2 diabetes
-
Nandy, D., Johnson, C., Basu, R., Joyner, M., Brett, J., Svendsen, C.B., Basu, A., The effect of liraglutide on endothelial function in patients with type 2 diabetes. Diab. Vasc. Dis. Res. 11 (2014), 419–430.
-
(2014)
Diab. Vasc. Dis. Res.
, vol.11
, pp. 419-430
-
-
Nandy, D.1
Johnson, C.2
Basu, R.3
Joyner, M.4
Brett, J.5
Svendsen, C.B.6
Basu, A.7
-
89
-
-
84893055427
-
Lipopolysaccharides-mediated increase in glucose-stimulated insulin secretion: involvement of the GLP-1 pathway
-
Nguyen, A.T., Mandard, S., Dray, C., Deckert, V., Valet, P., Besnard, P., Drucker, D.J., Lagrost, L., Grober, J., Lipopolysaccharides-mediated increase in glucose-stimulated insulin secretion: involvement of the GLP-1 pathway. Diabetes 63 (2014), 471–482.
-
(2014)
Diabetes
, vol.63
, pp. 471-482
-
-
Nguyen, A.T.1
Mandard, S.2
Dray, C.3
Deckert, V.4
Valet, P.5
Besnard, P.6
Drucker, D.J.7
Lagrost, L.8
Grober, J.9
-
90
-
-
84887728995
-
Tumour necrosis factor-alpha infusion produced insulin resistance but no change in the incretin effect in healthy volunteers
-
Nielsen, S.T., Lehrskov-Schmidt, L., Krogh-Madsen, R., Solomon, T.P., Lehrskov-Schmidt, L., Holst, J.J., Møller, K., Tumour necrosis factor-alpha infusion produced insulin resistance but no change in the incretin effect in healthy volunteers. Diabetes Metab. Res. Rev. 29 (2013), 655–663.
-
(2013)
Diabetes Metab. Res. Rev.
, vol.29
, pp. 655-663
-
-
Nielsen, S.T.1
Lehrskov-Schmidt, L.2
Krogh-Madsen, R.3
Solomon, T.P.4
Lehrskov-Schmidt, L.5
Holst, J.J.6
Møller, K.7
-
91
-
-
1442311383
-
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
-
Nikolaidis, L.A., Mankad, S., Sokos, G.G., Miske, G., Shah, A., Elahi, D., Shannon, R.P., Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109 (2004), 962–965.
-
(2004)
Circulation
, vol.109
, pp. 962-965
-
-
Nikolaidis, L.A.1
Mankad, S.2
Sokos, G.G.3
Miske, G.4
Shah, A.5
Elahi, D.6
Shannon, R.P.7
-
92
-
-
28144441354
-
Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy
-
Nikolaidis, L.A., Elahi, D., Shen, Y.T., Shannon, R.P., Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 289 (2005), H2401–H2408.
-
(2005)
Am. J. Physiol. Heart Circ. Physiol.
, vol.289
, pp. H2401-H2408
-
-
Nikolaidis, L.A.1
Elahi, D.2
Shen, Y.T.3
Shannon, R.P.4
-
93
-
-
84942673427
-
A Comparison of the Effects of the GLP-1 analogue liraglutide and insulin glargine on endothelial function and metabolic parameters: a randomized, controlled trial sapporo athero-incretin study 2 (SAIS2)
-
Nomoto, H., Miyoshi, H., Furumoto, T., Oba, K., Tsutsui, H., Miyoshi, A., Kondo, T., Tsuchida, K., Atsumi, T., Manda, N., et al., SAIS Study Group. A Comparison of the Effects of the GLP-1 analogue liraglutide and insulin glargine on endothelial function and metabolic parameters: a randomized, controlled trial sapporo athero-incretin study 2 (SAIS2). PLoS ONE, 10, 2015, e0135854.
-
(2015)
PLoS ONE
, vol.10
, pp. e0135854
-
-
Nomoto, H.1
Miyoshi, H.2
Furumoto, T.3
Oba, K.4
Tsutsui, H.5
Miyoshi, A.6
Kondo, T.7
Tsuchida, K.8
Atsumi, T.9
Manda, N.10
-
94
-
-
64649102619
-
GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice
-
Noyan-Ashraf, M.H., Momen, M.A., Ban, K., Sadi, A.M., Zhou, Y.Q., Riazi, A.M., Baggio, L.L., Henkelman, R.M., Husain, M., Drucker, D.J., GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58 (2009), 975–983.
-
(2009)
Diabetes
, vol.58
, pp. 975-983
-
-
Noyan-Ashraf, M.H.1
Momen, M.A.2
Ban, K.3
Sadi, A.M.4
Zhou, Y.Q.5
Riazi, A.M.6
Baggio, L.L.7
Henkelman, R.M.8
Husain, M.9
Drucker, D.J.10
-
95
-
-
84872055241
-
A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity
-
Noyan-Ashraf, M.H., Shikatani, E.A., Schuiki, I., Mukovozov, I., Wu, J., Li, R.K., Volchuk, A., Robinson, L.A., Billia, F., Drucker, D.J., Husain, M., A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation 127 (2013), 74–85.
-
(2013)
Circulation
, vol.127
, pp. 74-85
-
-
Noyan-Ashraf, M.H.1
Shikatani, E.A.2
Schuiki, I.3
Mukovozov, I.4
Wu, J.5
Li, R.K.6
Volchuk, A.7
Robinson, L.A.8
Billia, F.9
Drucker, D.J.10
Husain, M.11
-
96
-
-
84871686739
-
GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice
-
Panjwani, N., Mulvihill, E.E., Longuet, C., Yusta, B., Campbell, J.E., Brown, T.J., Streutker, C., Holland, D., Cao, X., Baggio, L.L., Drucker, D.J., GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology 154 (2013), 127–139.
-
(2013)
Endocrinology
, vol.154
, pp. 127-139
-
-
Panjwani, N.1
Mulvihill, E.E.2
Longuet, C.3
Yusta, B.4
Campbell, J.E.5
Brown, T.J.6
Streutker, C.7
Holland, D.8
Cao, X.9
Baggio, L.L.10
Drucker, D.J.11
-
97
-
-
84948740668
-
Lixisenatide in patients with type 2 diabetes and acute coronary syndrome
-
Pfeffer, M.A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H.C., Køber, L.V., Lawson, F.C., Ping, L., Wei, X., Lewis, E.F., et al., ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373 (2015), 2247–2257.
-
(2015)
N. Engl. J. Med.
, vol.373
, pp. 2247-2257
-
-
Pfeffer, M.A.1
Claggett, B.2
Diaz, R.3
Dickstein, K.4
Gerstein, H.C.5
Køber, L.V.6
Lawson, F.C.7
Ping, L.8
Wei, X.9
Lewis, E.F.10
-
98
-
-
84936166069
-
A randomized, controlled trial of 3.0 mg of liraglutide in weight management
-
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D.C., le Roux, C.W., Violante Ortiz, R., Jensen, C.B., Wilding, J.P., SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N. Engl. J. Med. 373 (2015), 11–22.
-
(2015)
N. Engl. J. Med.
, vol.373
, pp. 11-22
-
-
Pi-Sunyer, X.1
Astrup, A.2
Fujioka, K.3
Greenway, F.4
Halpern, A.5
Krempf, M.6
Lau, D.C.7
le Roux, C.W.8
Violante Ortiz, R.9
Jensen, C.B.10
Wilding, J.P.11
-
99
-
-
84959555725
-
Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database
-
Pizzimenti, V., Giandalia, A., Cucinotta, D., Russo, G.T., Smits, M., Cutroneo, P.M., Trifirò, G., Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database. J. Clin. Pharm. Ther. 41 (2016), 116–118.
-
(2016)
J. Clin. Pharm. Ther.
, vol.41
, pp. 116-118
-
-
Pizzimenti, V.1
Giandalia, A.2
Cucinotta, D.3
Russo, G.T.4
Smits, M.5
Cutroneo, P.M.6
Trifirò, G.7
-
100
-
-
84871675071
-
The glucagon-like peptide-1 receptor—or not?
-
Pyke, C., Knudsen, L.B., The glucagon-like peptide-1 receptor—or not?. Endocrinology 154 (2013), 4–8.
-
(2013)
Endocrinology
, vol.154
, pp. 4-8
-
-
Pyke, C.1
Knudsen, L.B.2
-
101
-
-
84897852105
-
GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody
-
Pyke, C., Heller, R.S., Kirk, R.K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., Knudsen, L.B., GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155 (2014), 1280–1290.
-
(2014)
Endocrinology
, vol.155
, pp. 1280-1290
-
-
Pyke, C.1
Heller, R.S.2
Kirk, R.K.3
Ørskov, C.4
Reedtz-Runge, S.5
Kaastrup, P.6
Hvelplund, A.7
Bardram, L.8
Calatayud, D.9
Knudsen, L.B.10
-
102
-
-
84860390563
-
A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans
-
Read, P.A., Hoole, S.P., White, P.A., Khan, F.Z., O'Sullivan, M., West, N.E., Dutka, D.P., A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ. Cardiovasc. Interv. 4 (2011), 266–272.
-
(2011)
Circ. Cardiovasc. Interv.
, vol.4
, pp. 266-272
-
-
Read, P.A.1
Hoole, S.P.2
White, P.A.3
Khan, F.Z.4
O'Sullivan, M.5
West, N.E.6
Dutka, D.P.7
-
103
-
-
84857111888
-
Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease
-
Read, P.A., Khan, F.Z., Dutka, D.P., Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart 98 (2012), 408–413.
-
(2012)
Heart
, vol.98
, pp. 408-413
-
-
Read, P.A.1
Khan, F.Z.2
Dutka, D.P.3
-
104
-
-
84897883235
-
Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model
-
Richards, P., Parker, H.E., Adriaenssens, A.E., Hodgson, J.M., Cork, S.C., Trapp, S., Gribble, F.M., Reimann, F., Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 63 (2014), 1224–1233.
-
(2014)
Diabetes
, vol.63
, pp. 1224-1233
-
-
Richards, P.1
Parker, H.E.2
Adriaenssens, A.E.3
Hodgson, J.M.4
Cork, S.C.5
Trapp, S.6
Gribble, F.M.7
Reimann, F.8
-
105
-
-
84867136387
-
Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice
-
Rieg, T., Gerasimova, M., Murray, F., Masuda, T., Tang, T., Rose, M., Drucker, D.J., Vallon, V., Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am. J. Physiol. Renal Physiol. 303 (2012), F963–F971.
-
(2012)
Am. J. Physiol. Renal Physiol.
, vol.303
, pp. F963-F971
-
-
Rieg, T.1
Gerasimova, M.2
Murray, F.3
Masuda, T.4
Tang, T.5
Rose, M.6
Drucker, D.J.7
Vallon, V.8
-
106
-
-
84962881180
-
Metabolically-inactive glucagon-like peptide-1(9-36)amide confers selective protective actions against post-myocardial infarction remodelling
-
Robinson, E., Tate, M., Lockhart, S., McPeake, C., O'Neill, K.M., Edgar, K.S., Calderwood, D., Green, B.D., McDermott, B.J., Grieve, D.J., Metabolically-inactive glucagon-like peptide-1(9-36)amide confers selective protective actions against post-myocardial infarction remodelling. Cardiovasc. Diabetol., 15, 2016, 65.
-
(2016)
Cardiovasc. Diabetol.
, vol.15
, pp. 65
-
-
Robinson, E.1
Tate, M.2
Lockhart, S.3
McPeake, C.4
O'Neill, K.M.5
Edgar, K.S.6
Calderwood, D.7
Green, B.D.8
McDermott, B.J.9
Grieve, D.J.10
-
107
-
-
84926648779
-
Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease
-
Sandoval, D.A., D'Alessio, D.A., Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol. Rev. 95 (2015), 513–548.
-
(2015)
Physiol. Rev.
, vol.95
, pp. 513-548
-
-
Sandoval, D.A.1
D'Alessio, D.A.2
-
108
-
-
84973167573
-
A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease
-
Scott, R.A., Freitag, D.F., Li, L., Chu, A.Y., Surendran, P., Young, R., Grarup, N., Stancáková, A., Chen, Y., Varga, T.V., et al. CVD50 consortium GERAD_EC Consortium Neurology Working Group of the Cohorts for Heart Aging Research in Genomic Epidemiology (CHARGE) Alzheimer's Disease Genetics Consortium Pancreatic Cancer Cohort Consortium European Prospective Investigation into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD) EPIC-InterAct CHARGE consortium CHD Exome+ Consortium, CARDIOGRAM Exome Consortium. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. Sci. Transl. Med., 8, 2016, 341ra76, 10.1126/scitranslmed.aad3744.
-
(2016)
Sci. Transl. Med.
, vol.8
, pp. 341ra76
-
-
Scott, R.A.1
Freitag, D.F.2
Li, L.3
Chu, A.Y.4
Surendran, P.5
Young, R.6
Grarup, N.7
Stancáková, A.8
Chen, Y.9
Varga, T.V.10
-
109
-
-
84925101632
-
Lowering blood glucose during hip surgery does not influence coagulation activation
-
Sechterberger, M.K., Hermanides, J., Poolman, R.W., Kal, J.E., Meijers, J.C., Hoekstra, J.B., Hans DeVries, J., Lowering blood glucose during hip surgery does not influence coagulation activation. BBA Clin. 3 (2015), 227–232.
-
(2015)
BBA Clin.
, vol.3
, pp. 227-232
-
-
Sechterberger, M.K.1
Hermanides, J.2
Poolman, R.W.3
Kal, J.E.4
Meijers, J.C.5
Hoekstra, J.B.6
Hans DeVries, J.7
-
110
-
-
84885031186
-
Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6
-
Shirazi, R., Palsdottir, V., Collander, J., Anesten, F., Vogel, H., Langlet, F., Jaschke, A., Schürmann, A., Prévot, V., Shao, R., et al. Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6. Proc. Natl. Acad. Sci. USA 110 (2013), 16199–16204.
-
(2013)
Proc. Natl. Acad. Sci. USA
, vol.110
, pp. 16199-16204
-
-
Shirazi, R.1
Palsdottir, V.2
Collander, J.3
Anesten, F.4
Vogel, H.5
Langlet, F.6
Jaschke, A.7
Schürmann, A.8
Prévot, V.9
Shao, R.10
-
111
-
-
84940751369
-
Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
-
Simó, R., Guerci, B., Schernthaner, G., Gallwitz, B., Rosas-Guzmàn, J., Dotta, F., Festa, A., Zhou, M., Kiljański, J., Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovasc. Diabetol., 14, 2015, 116.
-
(2015)
Cardiovasc. Diabetol.
, vol.14
, pp. 116
-
-
Simó, R.1
Guerci, B.2
Schernthaner, G.3
Gallwitz, B.4
Rosas-Guzmàn, J.5
Dotta, F.6
Festa, A.7
Zhou, M.8
Kiljański, J.9
-
112
-
-
84995609063
-
Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial
-
Skov, J., Pedersen, M., Holst, J.J., Madsen, B., Goetze, J.P., Rittig, S., Jonassen, T., Frøkiaer, J., Dejgaard, A., Christiansen, J.S., Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. Diabetes Obes. Metab. 18 (2016), 581–589.
-
(2016)
Diabetes Obes. Metab.
, vol.18
, pp. 581-589
-
-
Skov, J.1
Pedersen, M.2
Holst, J.J.3
Madsen, B.4
Goetze, J.P.5
Rittig, S.6
Jonassen, T.7
Frøkiaer, J.8
Dejgaard, A.9
Christiansen, J.S.10
-
113
-
-
33845293219
-
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
-
Sokos, G.G., Nikolaidis, L.A., Mankad, S., Elahi, D., Shannon, R.P., Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Card. Fail. 12 (2006), 694–699.
-
(2006)
J. Card. Fail.
, vol.12
, pp. 694-699
-
-
Sokos, G.G.1
Nikolaidis, L.A.2
Mankad, S.3
Elahi, D.4
Shannon, R.P.5
-
114
-
-
84990057324
-
Glucose-dependent insulinotropic peptide stimulates glucagon-like peptide 1 production by pancreatic islets via interleukin 6, produced by α cells
-
Published online March 10, 2016
-
Timper, K., Dalmas, E., Dror, E., Rütti, S., Thienel, C., Sauter, N.S., Bouzakri, K., Bédat, B., Pattou, F., Kerr-Conte, J., et al. Glucose-dependent insulinotropic peptide stimulates glucagon-like peptide 1 production by pancreatic islets via interleukin 6, produced by α cells. Gastroenterology, 2016, 10.1053/j.gastro.2016.03.003 Published online March 10, 2016.
-
(2016)
Gastroenterology
-
-
Timper, K.1
Dalmas, E.2
Dror, E.3
Rütti, S.4
Thienel, C.5
Sauter, N.S.6
Bouzakri, K.7
Bédat, B.8
Pattou, F.9
Kerr-Conte, J.10
-
115
-
-
84860204551
-
Cardiovascular biology of the incretin system
-
Ussher, J.R., Drucker, D.J., Cardiovascular biology of the incretin system. Endocr. Rev. 33 (2012), 187–215.
-
(2012)
Endocr. Rev.
, vol.33
, pp. 187-215
-
-
Ussher, J.R.1
Drucker, D.J.2
-
116
-
-
84901462249
-
Cardiovascular actions of incretin-based therapies
-
Ussher, J.R., Drucker, D.J., Cardiovascular actions of incretin-based therapies. Circ. Res. 114 (2014), 1788–1803.
-
(2014)
Circ. Res.
, vol.114
, pp. 1788-1803
-
-
Ussher, J.R.1
Drucker, D.J.2
-
117
-
-
84904283347
-
Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection
-
Ussher, J.R., Baggio, L.L., Campbell, J.E., Mulvihill, E.E., Kim, M., Kabir, M.G., Cao, X., Baranek, B.M., Stoffers, D.A., Seeley, R.J., Drucker, D.J., Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection. Mol. Metab. 3 (2014), 507–517.
-
(2014)
Mol. Metab.
, vol.3
, pp. 507-517
-
-
Ussher, J.R.1
Baggio, L.L.2
Campbell, J.E.3
Mulvihill, E.E.4
Kim, M.5
Kabir, M.G.6
Cao, X.7
Baranek, B.M.8
Stoffers, D.A.9
Seeley, R.J.10
Drucker, D.J.11
-
118
-
-
84922572669
-
Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment
-
von Scholten, B.J., Lajer, M., Goetze, J.P., Persson, F., Rossing, P., Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. Diabet. Med. 32 (2015), 343–352.
-
(2015)
Diabet. Med.
, vol.32
, pp. 343-352
-
-
von Scholten, B.J.1
Lajer, M.2
Goetze, J.P.3
Persson, F.4
Rossing, P.5
-
119
-
-
84952655093
-
Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium
-
Wallner, M., Kolesnik, E., Ablasser, K., Khafaga, M., Wakula, P., Ljubojevic, S., Thon-Gutschi, E.M., Sourij, H., Kapl, M., Edmunds, N.J., et al. Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium. J. Mol. Cell. Cardiol. 89:Pt B (2015), 365–375.
-
(2015)
J. Mol. Cell. Cardiol.
, vol.89
, pp. 365-375
-
-
Wallner, M.1
Kolesnik, E.2
Ablasser, K.3
Khafaga, M.4
Wakula, P.5
Ljubojevic, S.6
Thon-Gutschi, E.M.7
Sourij, H.8
Kapl, M.9
Edmunds, N.J.10
-
120
-
-
84938414413
-
Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas
-
Waser, B., Blank, A., Karamitopoulou, E., Perren, A., Reubi, J.C., Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas. Mod. Pathol. 28 (2015), 391–402.
-
(2015)
Mod. Pathol.
, vol.28
, pp. 391-402
-
-
Waser, B.1
Blank, A.2
Karamitopoulou, E.3
Perren, A.4
Reubi, J.C.5
-
121
-
-
84923206532
-
Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility
-
Wessel, J., Chu, A.Y., Willems, S.M., Wang, S., Yaghootkar, H., Brody, J.A., Dauriz, M., Hivert, M.F., Raghavan, S., Lipovich, L., et al., EPIC-InterAct Consortium. Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility. Nat. Commun., 6, 2015, 5897.
-
(2015)
Nat. Commun.
, vol.6
, pp. 5897
-
-
Wessel, J.1
Chu, A.Y.2
Willems, S.M.3
Wang, S.4
Yaghootkar, H.5
Brody, J.A.6
Dauriz, M.7
Hivert, M.F.8
Raghavan, S.9
Lipovich, L.10
-
122
-
-
84954571387
-
Cardiovascular effects of incretin-based therapies
-
White, W.B., Baker, W.L., Cardiovascular effects of incretin-based therapies. Annu. Rev. Med. 67 (2016), 245–260.
-
(2016)
Annu. Rev. Med.
, vol.67
, pp. 245-260
-
-
White, W.B.1
Baker, W.L.2
-
123
-
-
84960810832
-
The intestinal immune system in obesity and insulin resistance
-
Winer, D.A., Luck, H., Tsai, S., Winer, S., The intestinal immune system in obesity and insulin resistance. Cell Metab. 23 (2016), 413–426.
-
(2016)
Cell Metab.
, vol.23
, pp. 413-426
-
-
Winer, D.A.1
Luck, H.2
Tsai, S.3
Winer, S.4
-
124
-
-
84875299548
-
Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies
-
Wohlfart, P., Linz, W., Hübschle, T., Linz, D., Huber, J., Hess, S., Crowther, D., Werner, U., Ruetten, H., Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies. J. Transl. Med., 11, 2013, 84.
-
(2013)
J. Transl. Med.
, vol.11
, pp. 84
-
-
Wohlfart, P.1
Linz, W.2
Hübschle, T.3
Linz, D.4
Huber, J.5
Hess, S.6
Crowther, D.7
Werner, U.8
Ruetten, H.9
-
125
-
-
84883295202
-
Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study
-
Woo, J.S., Kim, W., Ha, S.J., Kim, J.B., Kim, S.J., Kim, W.S., Seon, H.J., Kim, K.S., Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler. Thromb. Vasc. Biol. 33 (2013), 2252–2260.
-
(2013)
Arterioscler. Thromb. Vasc. Biol.
, vol.33
, pp. 2252-2260
-
-
Woo, J.S.1
Kim, W.2
Ha, S.J.3
Kim, J.B.4
Kim, S.J.5
Kim, W.S.6
Seon, H.J.7
Kim, K.S.8
-
126
-
-
84861528676
-
Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans
-
Xiao, C., Bandsma, R.H., Dash, S., Szeto, L., Lewis, G.F., Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans. Arterioscler. Thromb. Vasc. Biol. 32 (2012), 1513–1519.
-
(2012)
Arterioscler. Thromb. Vasc. Biol.
, vol.32
, pp. 1513-1519
-
-
Xiao, C.1
Bandsma, R.H.2
Dash, S.3
Szeto, L.4
Lewis, G.F.5
-
127
-
-
38549146030
-
The murine glucagon-like peptide-1 receptor is essential for control of bone resorption
-
Yamada, C., Yamada, Y., Tsukiyama, K., Yamada, K., Udagawa, N., Takahashi, N., Tanaka, K., Drucker, D.J., Seino, Y., Inagaki, N., The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology 149 (2008), 574–579.
-
(2008)
Endocrinology
, vol.149
, pp. 574-579
-
-
Yamada, C.1
Yamada, Y.2
Tsukiyama, K.3
Yamada, K.4
Udagawa, N.5
Takahashi, N.6
Tanaka, K.7
Drucker, D.J.8
Seino, Y.9
Inagaki, N.10
-
128
-
-
0036307872
-
Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons
-
Yamamoto, H., Lee, C.E., Marcus, J.N., Williams, T.D., Overton, J.M., Lopez, M.E., Hollenberg, A.N., Baggio, L., Saper, C.B., Drucker, D.J., Elmquist, J.K., Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J. Clin. Invest. 110 (2002), 43–52.
-
(2002)
J. Clin. Invest.
, vol.110
, pp. 43-52
-
-
Yamamoto, H.1
Lee, C.E.2
Marcus, J.N.3
Williams, T.D.4
Overton, J.M.5
Lopez, M.E.6
Hollenberg, A.N.7
Baggio, L.8
Saper, C.B.9
Drucker, D.J.10
Elmquist, J.K.11
-
129
-
-
84962086818
-
GLP-1R agonists modulate enteric immune responses through the intestinal intraepithelial lymphocyte GLP-1R
-
Yusta, B., Baggio, L.L., Koehler, J., Holland, D., Cao, X., Pinnell, L.J., Johnson-Henry, K.C., Yeung, W., Surette, M.G., Bang, K.W., et al. GLP-1R agonists modulate enteric immune responses through the intestinal intraepithelial lymphocyte GLP-1R. Diabetes 64 (2015), 2537–2549.
-
(2015)
Diabetes
, vol.64
, pp. 2537-2549
-
-
Yusta, B.1
Baggio, L.L.2
Koehler, J.3
Holland, D.4
Cao, X.5
Pinnell, L.J.6
Johnson-Henry, K.C.7
Yeung, W.8
Surette, M.G.9
Bang, K.W.10
-
130
-
-
84929485368
-
Differential patterns and determinants of cardiac autonomic nerve dysfunction during endotoxemia and oral fat load in humans
-
Ziegler, D., Strom, A., Strassburger, K., Nowotny, B., Zahiragic, L., Nowotny, P.J., Carstensen-Kirberg, M., Herder, C., Szendroedi, J., Roden, M., Differential patterns and determinants of cardiac autonomic nerve dysfunction during endotoxemia and oral fat load in humans. PLoS ONE, 10, 2015, e0124242.
-
(2015)
PLoS ONE
, vol.10
, pp. e0124242
-
-
Ziegler, D.1
Strom, A.2
Strassburger, K.3
Nowotny, B.4
Zahiragic, L.5
Nowotny, P.J.6
Carstensen-Kirberg, M.7
Herder, C.8
Szendroedi, J.9
Roden, M.10
-
131
-
-
84944800184
-
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
-
Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O.E., Woerle, H.J., et al., EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373 (2015), 2117–2128.
-
(2015)
N. Engl. J. Med.
, vol.373
, pp. 2117-2128
-
-
Zinman, B.1
Wanner, C.2
Lachin, J.M.3
Fitchett, D.4
Bluhmki, E.5
Hantel, S.6
Mattheus, M.7
Devins, T.8
Johansen, O.E.9
Woerle, H.J.10
|